LLY
ELI LILLY & Co
NYSE · Healthcare · Drug Manufacturers - General · US
$1,152.22
−0.02%Year over year
Reported trailing growth
- Revenue
- +49.6%
- EBITDA
- +120.3%
- EBIT
- +73.9%
- EPS
- +94.6%
- Free cash flow
- —
- Operating cash flow
- +156.7%
Forward estimates
Based on analyst estimates
- Revenue
- +16.0%
- EBITDA
- +9.3%
- EPS
- +36.7%
Three-year CAGR
- Revenue
- +31.7%
- EBITDA
- +54.1%
- EBIT
- +50.8%
- Net income
- +49.0%
- EPS
- +52.0%
- Free cash flow
- +24.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026